Rocket Pharmaceuticals, Inc. RCKT

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
43/100
Developing

Ranked against 712 peers in Biotechnology

About Rocket Pharmaceuticals, Inc.

Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases in the United States. It develops vivo adeno-associated viral (AAV) programs, which include programs for Danon disease (DD), a multi-organ lysosomal-associated disorder leading to early death due to heart failure (RP-A501), which is in Phase 2 … Full RCKT analysis →

Key strengths

  • Strong Liquidity Buffer Liquidity position is strong (score 0.64), providing operational cushion.

Key risks

  • ROIC Below WACC or Peers ROIC at 35.8th percentile suggests inefficient capital deployment.
  • Elevated Debt Risk Debt serviceability is weak (score 0.31), raising refinancing risk.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where RCKT ranks in Biotechnology

Rocket Pharmaceuticals, Inc. ranks #337 of 713 scored companies in Biotechnology by moat score — the top 47%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
333 Palatin Technologies, Inc. PTN 43/100 Developing
334 Savara, Inc. SVRA 43/100 Developing
335 Mersana Therapeutics, Inc. MRSN 43/100 Developing
336 Neuphoria Therapeutics Inc. NEUP 43/100 Developing
337 Rocket Pharmaceuticals, Inc. RCKT 43/100 Developing
338 Vaxcyte, Inc. PCVX 43/100 Developing
339 Chemomab Therapeutics Ltd. CMMB 42/100 Developing
340 Solid Biosciences Inc. SLDB 42/100 Developing
341 60 Degrees Pharmaceuticals, Inc SXTP 42/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How RCKT scores on the Corporate Default defenses

Pricing Power

Not measurable · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Not measurable · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Not measurable · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 42 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 43 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Not measurable · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding RCKT's moat

What is Rocket Pharmaceuticals, Inc.'s moat score?

Rocket Pharmaceuticals, Inc. (RCKT) scores 43 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #337 of 713 scored companies in Biotechnology, the top 47%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Resilience (43/100) and its weakest is Capital Efficiency (42/100).

How does Rocket Pharmaceuticals, Inc. compare with other Biotechnology companies?

Rocket Pharmaceuticals, Inc. ranks #337 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Neuphoria Therapeutics Inc. (NEUP) at 43 just above it and Vaxcyte, Inc. (PCVX) at 42 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Rocket Pharmaceuticals, Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Rocket Pharmaceuticals, Inc.?

The Corporate Default template measures 6 defenses, and RCKT scores: Pricing Power (not measurable), Cost Advantage (not measurable), Customer Stickiness (not measurable), Capital Efficiency (42), Resilience (43), Scale & Market Position (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000